Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Diabetes Drug Prevents Alzheimer's Disease in Mouse Model

By LabMedica International staff writers
Posted on 06 Dec 2010
The biguanide drug metformin, which is used to treat type II diabetes, has been found to block phosphorylation of the tau proteins that are present in insoluble tangles in the brains of Alzheimer's disease patients.

Hyperphosphorylation of the tau protein can result in the self-assembly of tangles of paired helical filaments and straight filaments, which are involved in the pathogenesis of Alzheimer's disease and other tauopathies. More...
When misfolded, this otherwise very soluble protein can form extremely insoluble aggregates that contribute to a number of neurodegenerative diseases.

Investigators at the German Center for Neurodegenerative Diseases (Munich) and their colleagues at the University of Dundee (United Kingdom) and the Max-Planck-Institute for Molecular Genetics (Berlin, Germany) were seeking drugs that would block phosphorylation of tau proteins and prevent the destruction of brain neurons.

In the current study they focused on the diabetes drug metformin, which was known to activate the enzyme protein phosphatase 2A (PP2A), the major tau phosphatase. Activation of PP2A would be expected to reverse tau hyperphosphorylation.

The investigators worked with both cell cultures - primary neurons taken from wild type and human tau transgenic mice - and in vivo with the two different lines of mice. They reported in the November 22, 2010, online edition of the journal Proceedings of the [US] National Academy of Sciences (PNAS) that metformin induced PP2A activity and reduced tau phosphorylation at PP2A-dependent epitopes in vitro and in vivo. This tau dephosphorylating potency could be blocked entirely by the PP2A inhibitors okadaic acid and fostriecin, confirming that PP2A was an important mediator of the observed effects. Affinity chromatography and immunoprecipitation experiments together with PP2A activity assays indicated that metformin interfered with the binding properties of the catalytic subunit of PP2A and thereby influenced PP2A activity.

"So far there is no drug on the market that targets the formation of tau aggregates,” said contributing author Dr. Sybille Krauss, a researcher at the German Center for Neurodegenerative Diseases. "If we can confirm that metformin shows also an effect in humans, it is certainly a good candidate for an effective therapy on Alzheimer's diseases.”

Related Links:

German Center for Neurodegenerative Diseases
University of Dundee
Max-Planck-Institute for Molecular Genetics




Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.